Jump to Main Content
Suppression of cancer relapse and metastasis by inhibiting cancer stemness
- Li, Youzhi, Rogoff, Harry A., Keates, Sarah, Gao, Yuan, Murikipudi, Sylaja, Mikule, Keith, Leggett, David, Li, Wei, Pardee, Arthur B., Li, Chiang J.
- Proceedings of the National Academy of Sciences of the United States of America 2015 v.112 no.6 pp. 1839-1844
- humans, medicine, metastasis, neoplasm cells, neoplasms, patients, relapse, stem cells, therapeutics
- Significance Current cancer treatments ultimately fail owing to metastasis and relapse. The discovery of therapeutic approaches that counteract relapse and metastasis is, therefore, extremely important for advancing cancer medicine. Hypermalignant cancer cells, termed cancer stem cells or stemness-high cancer cells, have been isolated from patients with a variety of tumor types and found to be highly malignant, tumorigenic, and resistant to chemotherapies. Our data that BBI608, a cancer stemness inhibitor in clinical development, effectively blocks cancer relapse and metastasis in xenografted human cancers, suggest targeting cancer stemness as a novel approach to develop the next generation of cancer therapeutics to suppress cancer relapse and metastasis.